Target diseasesAge-related macular degeneration (AMD): This is a disease that affects the RPE layer of the retina and ranks third among the global causes of visual impairment. It is estimated that about 1.5 Cr to 4 Cr people in India suffer from AMD.Retinitis pigmentosa (RP): RP is estimated to affect 1 in 4000 people in the west. However, the prevalence in India is estimated to be much higher (as high as 1 in 350 in some states). RP affects the Photoreceptor (PR) layer of the eye and manifests largely at a very early age with eventual progression to blindness.Our product roadmapWe have succesfully differentiated RPE and PR from induced pluripotent stem cells through a novel, patentable protocol. We are currently in the process of taking these cell products through pre-clinical and clinical trials.We are also pursuing a unique approach towards creating a cell that can evade immune rejection from the body. Such a cell type can make allogeneic therapy truly scalable without the need for immune suppression or HLA typing and will represent a paradigm shift in the field of cell therapy.Our platform strategyEyestem’s medium term vision is to create a platform for cell therapy which makes cell products truly scalable for several other disease areas where such therapy can play a critical role. Our core competence in cellular differentiation, product manufacturing, and translational regulatory expertise will provide us the platform to move into therapies for other degenerative diseases of the body.